Patents by Inventor Vladimir H. Voynov

Vladimir H. Voynov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TRKB ANTIBODIES
    Publication number: 20240101689
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 28, 2023
    Publication date: March 28, 2024
    Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20240052065
    Abstract: The present invention relates to novel binding molecules. The invention specifically relates to binding molecules that bind to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-3 (CDH3). The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: July 13, 2023
    Publication date: February 15, 2024
    Inventors: Juan Manuel GARCIA-MARTINEZ, Stephan GLASER, Gale Lee HANSEN, Srinath KASTURIRANGAN, Klaus-Peter KUENKELE, Vladimir H. VOYNOV, Andreas WERNITZNIG, Chao ZHENG
  • Anti-TrkB antibodies
    Patent number: 11866501
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: January 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Katharina Florin, Cynthia Hess Kenny, Sarah Kathleen Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir H. Voynov, Haiguang Xiao
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20230340130
    Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 20, 2023
    Publication date: October 26, 2023
    Inventors: Susanne HIPP, Paul ADAM, Michael DZIEGELEWSKI, Rajukumar GANESAN, Phillip Nicholas GORMAN, Pankaj GUPTA, Priyanka GUPTA, Marcio LASARO, Justin M. SCHEER, Vladimir H. VOYNOV
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20230295337
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 1, 2023
    Publication date: September 21, 2023
    Inventors: Susanne HIPP, Paul ADAM, Michael DZIEGELEWSKI, Rajkumar GANESAN, Philip Nicholas GORMAN, Pankaj GUPTA, Priyanka GUPTA, Justin SCHEER, Vladimir H. VOYNOV
  • Multi-specific binding proteins for cancer treatment
    Patent number: 11732045
    Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 22, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Pankaj Gupta, Priyanka Gupta, Marcio Lasaro, Justin M. Scheer, Vladimir H. Voynov
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20220251236
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: March 4, 2022
    Publication date: August 11, 2022
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj GUPTA
  • Multi-specific binding proteins for cancer treatment
    Patent number: 11332541
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 17, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
  • ANTI-TRKB ANTIBODIES
    Publication number: 20200399378
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 24, 2020
    Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20190375849
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 12, 2019
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov